Online inquiry

IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11384MR)

This product GTTS-WQ11384MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IGF1&IGF2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000618.5; NM_000612.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3479; 3481
UniProt ID P05019; P01344
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ11384MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15540MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ2967MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ANB020
GTTS-WQ12324MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ16005MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ6022MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ3255MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ART621
GTTS-WQ8457MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HspE7
GTTS-WQ14635MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW